The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2622-2631

  Zheng, Shan ^a   Bai, Jing Qiao ^a   Li, Jing ^a   Fan, Jin Hu ^a   Pang, Yi ^a,b   Song, Qing Kun ^a   Huang, Rong ^a,b   Yang, Hong Jian ^c   Xu, Feng ^d   Lu, Ning ^a   Qiao, You Lin ^a  

^a CANCER HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

breast carcinoma; ethnic populations; pathologic characteristics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER STAGING; CHINA; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; GENE OVEREXPRESSION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHINA; CROSS-SECTIONAL STUDIES; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84867058276     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27513     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, Fitch M, Groot M, Sancho-Garnier H, Tsu VD,. Breast cancer in limited-resource countries: health care systems and public policy. Breast J 2006; 12 (Suppl 1): S54 -69.
3. Statistical information Team, Cancer Research UK, Breast cancer. 2009 (http://info.cancerresearchuk.org/cancerstats/types/breast/mortality/).
4. Stewart B, Kleihues PE,. World cancer report. Lyon: IARC Press, 2003.
5. Porter PL,. Global trends in breast cancer incidence and mortality. Salud Publ Mex 2009; 51 (Suppl 2): s141-s6.
6. Anderson BO, Braun S, Carlson RW, Gralow JR, Lagios MD, Lehman C, Schwartsmann G, Vargas HI,. Overview of breast health care guidelines for countries with limited resources. Breast J 2003; 9 (Suppl 2): S42-S50.
7. Anderson BO, Braun S, Lim S, Smith RA, Taplin S, Thomas DB,. Early detection of breast cancer in countries with limited resources. Breast J 2003; 9 (Suppl 2): S51-S9.
8. Shyyan R, Sener SF, Anderson BO, Garrote LM, Hortobagyi GN, Ibarra JA, Jr, Ljung BM, Sancho-Garnier H, Stalsberg H,. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer 2008; 113: 2257-68.
9. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E,. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-32.
10. Shyyan R, Masood S, Badwe RA, Errico KM, Liberman L, Ozmen V, Stalsberg H, Vargas H, Vass L,. Breast cancer in limited-resource countries: diagnosis and pathology. Breast J 2006; 12 (Suppl 1): S27-S37.
11. Masood S, Vass L, Ibarra JA Jr, Ljung BM, Stalsberg H, Eniu A, Carlson RW, Anderson BO,; Breast Health Global Initiative Pathology Focus Group. Implementation of breast pathology guidelines for countries of limited resources. Cancer 2008; 113 (Suppl 8): 2297-304.
12. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masetti R, Anderson BO,. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer 2008; 113: 2269-81.
13. Zarbo RJ, Hammond ME,. Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 2003; 127: 549-53.
14. Olefsky JM,. Nuclear receptor minireview series. J Biol Chem 2001; 276: 36863-4.
15. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA,. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004; 10: 2751-60.
16. Olayioye MA, Neve RM, Lane HA, Hynes NE,. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67.
17. Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR,. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
18. Chen XY, Kong ZL,. Chinese cancer registry annual report 2009. Beijing: Military Medical Science Press, 2010. 26-37.
19. National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health. National survey on cancer mortality in china-the third sample survey on mortality. Beijing: The People's Health Press, 2010. 10-22.
20. Murff HJ, Shu XO, Li H, Yang G, Wu X, Cai H, Wen W, Gao YT, Zheng W,. Dietary polyunsaturated fatty acids and breast cancer risk in Chinese women: a prospective cohort study. Int J Cancer 2011; 128: 1434-41.
21. Zhang M, Huang J, Xie X, Holman CD,. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer 2009; 124: 1404-8.
22. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA,. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst 2008; 100: 1352-60.
23. Kwong A, Cheung P, Chan S, Lau S,. Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 2008; 32: 2554-61.
24. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM,. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009; 115: 325-33.
25. Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM,. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 2009; 117: 409-16.
26. Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS,. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 2009; 100: 563-70.
27. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of breast cancer in china. BMC cancer, 2011; 11: 364.
28. WHO. Histological typing of breast tumors, 2nd edn, Geneva: WHO, 1981. 15-26.
29. Tavassoli FA, Devilee P,. Pathology and Genetics of tumours of the breast and female genital organs. Lyon: IARC, 2003: 221-32.
30. American Joint Committee on Cancer. AJCC cancer staging manual, 5th edn, Philadelphia: Lippincott-Raven, 1997. 171-80.
31. American Joint Committee on Cancer. AJCC cancer staging manual, 6th edn, New York: Springer, 2002: 223-40.
32. Hausauer AK, Keegan TH, Chang ET, Clarke CA,. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res 2007; 9: R90.
33. Bates T, Kearins O, Monypenny I, Lagord C, Lawrence G,. Clinical outcome data for symptomatic breast cancer: the Breast Cancer Clinical Outcome Measures (BCCOM) Project. Br J Cancer 2009; 101: 395-402.
34. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE,. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis. BMC Cancer 2010; 10: 191.
35. Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, et al. ONCOPOOL-a European database for 16,944 cases of breast cancer. Eur J Cancer 2010; 46: 56-71.
36. Bordoni A, Probst-Hensch NM, Mazzucchelli L, Spitale A,. Assessment of breast cancer opportunistic screening by clinical-pathological indicators: a population-based study. Br J Cancer 2009; 101: 1925-31.
37. Owens MA, Horten BC, Da Silva MM,. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9.
38. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO,. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.
39. National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health. National survey on cancer mortality in china. Beijing: The People's Health Press, 2010: 120-31.
40. Lokuhetty MD, Ranaweera GG, Wijeratne MD, Wickramasinghe KH, Sheriffdeen AH,. Profile of breast cancer in a group of women in a developing country in South Asia: is there a difference? World J Surg 2009; 33: 455-9.
41. Lim SE, Back M, Quek E, Iau P, Putti T, Wong JE,. Clinical observations from a breast cancer registry in Asian women. World J Surg 2007; 31: 1387-92.
42. Chuwa EW, Yeo AW, Koong HN, Wong CY, Yong WS, Tan PH, Ho JT, Wong JS, Ho GH,. Early detection of breast cancer through population-based mammographic screening in Asian women: a comparison study between screen-detected and symptomatic breast cancers. Breast J 2009; 15: 133-9.
43. Kuraparthy S, Reddy KM, Yadagiri LA, Yutla M, Venkata PB, Kadainti SV, Reddy RP,. Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol 2007; 5: 56.
44. Majid RA, Mohammed HA, Saeed HM, Safar BM, Rashid RM, Hughson MD,. Breast cancer in Kurdish women of northern Iraq: incidence, clinical stage, and case control analysis of parity and family risk. BMC Womens Health 2009; 9: 33.
45. Harirchi I, Karbakhsh M, Montazeri A, Ebrahimi M, Jarvandi S, Zamani N, Momtahen AJ, Kashefi A, Zafarghandi MR,. Decreasing trend of tumor size and downstaging in breast cancer in Iran: results of a 15-year study. Eur J Cancer Prev 2010; 19: 126-30.
46. Rezaianzadeh A, Peacock J, Reidpath D, Talei A, Hosseini SV, Mehrabani D,. Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran. BMC Cancer 2009; 9: 168.
47. Ko SS,. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008; 98: 318-23.
48. National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health. National survey on cancer incidence and mortality in China-the third volumn (1998-2002). Beijing: Beijing: The People's Health Press, 2007. 302-07
49. Ding SL, Yu JC, Chen ST, Hsu GC, Hsu HM, Ho JY, Lin YH, Chang CC, Fann CS, Cheng CW, Wu PE, Shen CY,. Diverse associations between ESR1 polymorphism and breast cancer development and progression. Clin Cancer Res 2010; 16: 3473-84.
50. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70: 5207-12.